Literature DB >> 30928408

Nicotinamide riboside protects against liver fibrosis induced by CCl4 via regulating the acetylation of Smads signaling pathway.

Rui Jiang1, Yujia Zhou2, Sufan Wang2, Nengzhi Pang2, Yuanling Huang2, Mingtong Ye2, Ting Wan2, Yun Qiu2, Lei Pei2, Xuye Jiang2, Yufeng Huang3, Hainan Yang3, Wenhua Ling2, Xufeng Li4, Zhenfeng Zhang5, Lili Yang6.   

Abstract

AIMS: Increasing nicotinamide adenine dinucleotide (NAD+) by Nicotinamide riboside (NR) provides protective benefits in multiple disorders. However, the role of NR on liver fibrosis is unclear. We performed in vivo and in vitro experiments to test the hepatic protective effects of NR against liver fibrosis and the underlying mechanisms.
MATERIALS AND METHODS: Mice were injected with CCl4 to establish liver fibrosis model. NR was given by gavage to explore the hepatic protection of NR. LX-2 cells were given a TGF-β stimulation ± NR, the activation of LX-2 cells and the acetylation of Smads were analyzed. To further confirm the role of Sirt1 on the protective pathway of NR, we knockdown Sirt1 in LX-2 cells. KEY
FINDINGS: We found NR could prevent liver fibrosis and reverse the existing liver fibrosis. NR inhibited the activation of LX-2 cells induced by TGF-β, activated Sirt1 and deacetylated Smad2/3. Sirt1 knockdown diminished the inhibiting effect of NR on LX-2 cells activation, and increased expressions of acetylated Smads. In conclusion, NR could prevent liver fibrosis via suppressing activation of hepatic stellate cells (HSCs). This protective effect was mediated by regulating the acetylation of Smads signaling pathway. SIGNIFICANCE: NR protected mice against liver fibrosis induced by CCl4. NR suppressed activation of hepatic stellate cells induced by TGF-β. NR protects liver fibrosis via increasing the activity of Sirt1 and decreasing the expression of P300, resulting in the deacetylation of Smads in stellate cells.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deacetylation; HSCs; Nicotinamide riboside; P300; Sirt1; TGF-β

Mesh:

Substances:

Year:  2019        PMID: 30928408     DOI: 10.1016/j.lfs.2019.03.064

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  8 in total

1.  Inhibition of miRNA‑135a‑5p ameliorates TGF‑β1‑induced human renal fibrosis by targeting SIRT1 in diabetic nephropathy.

Authors:  Juan Zhang; Lian Zhang; Dongqing Zha; Xiaoyan Wu
Journal:  Int J Mol Med       Date:  2020-06-17       Impact factor: 4.101

2.  Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy.

Authors:  Qingquan Chen; Yu Zeng; Xiulin Yang; Yue Wu; Shuyu Zhang; Shirong Huang; Yameng Zhong; Min Chen
Journal:  BMC Cardiovasc Disord       Date:  2022-01-26       Impact factor: 2.298

3.  MALAT1 promotes liver fibrosis by sponging miR‑181a and activating TLR4‑NF‑κB signaling.

Authors:  Yinghui Wang; Qiuju Mou; Zixin Zhu; Luqiang Zhao; Lili Zhu
Journal:  Int J Mol Med       Date:  2021-10-15       Impact factor: 4.101

Review 4.  Emerging Role of Nicotinamide Riboside in Health and Diseases.

Authors:  Chiranjeev Sharma; Dickson Donu; Yana Cen
Journal:  Nutrients       Date:  2022-09-20       Impact factor: 6.706

Review 5.  Epigenetic Regulation of Hepatic Stellate Cell Activation and Macrophage in Chronic Liver Inflammation.

Authors:  Chun-Xia Shi; Yao Wang; Fang-Zhou Jiao; Qian Chen; Pan Cao; Mao-Hua Pei; Lu-Yi Zhang; Jin Guo; Wei Deng; Lu-Wen Wang; Zuo-Jiong Gong
Journal:  Front Physiol       Date:  2021-07-01       Impact factor: 4.566

6.  Nicotinamide riboside exerts protective effect against aging-induced NAFLD-like hepatic dysfunction in mice.

Authors:  Xue Han; Xiaogang Bao; Qi Lou; Xian Xie; Meng Zhang; Shasang Zhou; Honggang Guo; Guojun Jiang; Qiaojuan Shi
Journal:  PeerJ       Date:  2019-08-28       Impact factor: 2.984

Review 7.  TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019.

Authors:  Bedair Dewidar; Christoph Meyer; Steven Dooley; And Nadja Meindl-Beinker
Journal:  Cells       Date:  2019-11-11       Impact factor: 6.600

Review 8.  Epigenetics in Liver Fibrosis: Could HDACs be a Therapeutic Target?

Authors:  Alex Claveria-Cabello; Leticia Colyn; Maria Arechederra; Jesus M Urman; Carmen Berasain; Matias A Avila; Maite G Fernandez-Barrena
Journal:  Cells       Date:  2020-10-19       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.